Carisma Therapeutics, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Carisma Therapeutics, Inc. (NasdaqGM: CARM) develops engineered macrophage and monocyte immunotherapies targeting fibrosis, solid tumors, and autoimmune disorders; its core offerings include CT-1119, an ex vivo autologous CAR-Monocyte therapy in Phase 1 for mesothelin-positive solid tumors such as pancreatic, ovarian, lung, and mesothelioma cancers; CT-2401, a preclinical TIM4 mRNA-loaded Kupffer cell tropic LNP therapy to repair efferocytosis and reduce liver fibrosis; and in vivo CAR-Macrophage therapies, led by an anti-glypican 3 (GPC3) program for hepatocellular carcinoma in collaboration with Moderna Therapeutics, alongside four additional nominated oncology targets and options for up to seven more, plus two autoimmune research programs. The Philadelphia-based company, founded in 2016 and headquartered at 3675 Market Street, Pennsylvania, operates primarily in the United States within the biotechnology sector, focusing on oncology, fibrosis, and autoimmune segments through its proprietary chimeric antigen receptor macrophage (CAR-M) platform that engages innate and adaptive immune responses against tumors. Recent strategic shifts include a December 2024 pipeline reprioritization and 34% workforce reduction to focus on off-the-shelf in vivo macrophage engineering for fibrosis, oncology, and autoimmune therapies, discontinuing the anti-HER2 (CT-0525) program by early 2025; a June 2025 definitive merger agreement with OrthoCellix Inc., Ocugen Inc.'s subsidiary, to advance NeoCart cartilage therapy, terminated in September 2025 due to funding shortfalls; and a September 2025 Moderna collaboration amendment recognizing $45.3 million in fully paid-up license revenue.
Critical Review: Carisma Therapeutics (NASDAQ:CARM) vs. Protalex (OTCMKTS:PRTX)
Carmila: 2025 Annual Results
Financial Comparison: Context Therapeutics (NASDAQ:CNTX) vs. Carisma Therapeutics (NASDAQ:CARM)
Carisma Announces Delisting from Nasdaq and SEC Deregistration
Head-To-Head Survey: Achieve Life Sciences (NASDAQ:ACHV) vs. Carisma Therapeutics (NASDAQ:CARM)
Carmanah Minerals Engages Warrior Drilling for Heritage Project; Targets Historic Eagle Zone on Burin Trend, NL
Comparing Cassava Sciences (NASDAQ:SAVA) and Carisma Therapeutics (NASDAQ:CARM)
Carmila - First-half 2025 Results: Acceleration in Growth and Recurring Earnings Outlook Revised Upwards
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BASE, CARM, ENZB on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CARM, ENZB, GNTY on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BASE and CARM on Behalf of Shareholders
CARM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Carisma Therapeutics Inc. Is Fair to Shareholders
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
Carisma Therapeutics Provides Corporate Updates
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline
Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma